Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 12 845 / https://doi.org/10.3332/ecancer.2018.845

Research

Correlation of BMI with breast cancer subtype and tumour size

Background: Breast cancer is a heterogeneous disease which is divided broadly into luminal, HER2 and basal type based on molecular profiling. Increased body mass index (BMI) has been associated with the risk of developing breast cancer but the association based on molecular subtype remains conflicting.

Methods: This was an observational study carried out over a period of 2 years. Nonmetastatic breast cancer patients were evaluated for the tumour subtype based on surrogate markers (ER, PR and HER2). The BMI of these patients was correlated with the tumour subtype and size.

Results: We studied 476 patients with breast cancer with the median age of 46 years (range, 25–86) and 58% were premenopausal. The mean BMI of the cohort was 24.1, which was significantly higher in postmenopausal women (24.9 versus 23.6, p < 0.05). Overall, only 10% of patients were obese. The mean BMI in the luminal, HER2 and TNBC subtypes was 24.7, 22.4 and 23.9, respectively (p < 0.01). Also, the mean tumour size in luminal, HER2 and TNBC subtype was 4.02, 3.80 and 4.27 cm, respectively (p = 0.158).

Conclusion: The average BMI was higher in patients with luminal subtype followed by TNBC and lowest for HER2 at the time of diagnosis. The mean tumour size was numerically higher for TNBC and lowest for HER2 subtype although the difference was not statistically significant. Larger studies may provide clarity of association between the BMI and tumour subtype.

Keywords: Body mass index, breast cancer

Categories:

Breast

Loading Article Metrics ... Please wait

Related articles

Case Report: Use of PEG-asparaginase in a case of Hepatosplenic γδ T-cell lymphoma with long-term remission after stem cell transplantation

Abstract | Full Article | PDF Published: 20 Sep 2018 / https://doi.org/10.3332/ecancer.2018.872

Conference Report: Highlights from the 2018 WIN Symposium, 25–26 June 2018, Paris: designing the future of precision oncology

Abstract | Full Article | PDF Published: 12 Sep 2018 / https://doi.org/10.3332/ecancer.2018.871

Conference Report: Inspiration, innovation and integration: highlights from the third ICPCN conference on children’s palliative care, 30th May-2nd June 2018, Durban, South Africa

Abstract | Full Article | PDF Published: 11 Sep 2018 / https://doi.org/10.3332/ecancer.2018.870

Special Issue: Pre-, pro- and synbiotics in cancer prevention and treatment—a review of basic and clinical research

Abstract | Full Article | PDF Published: 05 Sep 2018 / https://doi.org/10.3332/ecancer.2018.869

Special Issue: Gut microbiota, chemotherapy and the host: the influence of the gut microbiota on cancer treatment

Abstract | Full Article | PDF Published: 05 Sep 2018 / https://doi.org/10.3332/ecancer.2018.868



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation